Sinovent

About Sinovent

Established in 2011 by founder Dr. De-Chao Yu, Innovent Biologics, Inc. (operating as Sinovent), has positioned itself as a biopharmaceutical company headquartered in Suzhou, China. Dr. Yu, an alumnus of Zhejiang University with a Ph.D. from the Chinese Academy of Sciences and postdoctoral studies at the University of California, San Francisco, brought nearly three decades of experience in the innovative medicine field, including executive roles at U.S. firms like Calydon and Applied Genetic Technology, to the founding of the company. Innovent's inception was driven by the goal of developing high-quality biologics for the broader population.

The company focuses on the development, manufacturing, and commercialization of drugs for major diseases such as oncology, cardiovascular and metabolic (CVM), autoimmune, and ophthalmology. Its business model revolves around a fully integrated platform that spans from research and development and clinical trials to manufacturing and commercial sales. Revenue is primarily generated from the sale of its portfolio of approved drugs and strategic partnerships. A significant milestone in its history was the strategic collaboration with Eli Lilly, which involved a substantial upfront payment and potential for over $1 billion in milestone payments, accelerating the development of its product pipeline. Innovent successfully went public on the Hong Kong Stock Exchange on October 31, 2018.

Innovent's product pipeline is extensive, featuring various drug formats like monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and cell therapies. One of its key products is Tyvyt® (sintilimab injection), a PD-1 monoclonal antibody developed for treating certain types of lymphoma and other cancers. The company has a growing portfolio of commercialized products, including drugs for various cancers and metabolic diseases. Recent developments highlight the company's expansion into a dual-engine growth strategy, focusing on both oncology and chronic diseases, exemplified by the approval of Mazdutide, a GLP-1/GCGR dual agonist for metabolic conditions, and promising clinical data for its PD-1/IL-2α bispecific antibody, IBI363.